Since anti-HER2 therapy enhances the therapeutic efficacy of chemotherapy, the antibody–drug conjugate (ADC) class of drugs was developed to maximize the cytotoxic effect of anti-HER2 therapy and chemotherapy via endocytosis selectively in HER2+ tumor cells [6]. The gene discussed is ERBB2; the disease is neoplasm.